Aplastica anemia and XXXX .

@entity99 @entity5066 @entity2150 @entity1897 @entity2131 @entity3043
@entity2150 ( @entity2150 ) is a severe and rare disease, characterized by hematopoietic @entity2131 and @entity1897 . The pathophysiology is immune mediated in most cases, activated T1 lymphocytes have been identified as effector cells. The disease can be successfully treated with combined immunosuppressive therapy or allogeneic hematopoietic stem cell transplantation. @entity2150 ( @entity2150 ) is a syndrome of @entity2131 following the development of @entity99 . @entity2150 syndrome most often affects young males who presented severe @entity3043 two to three months after an episode of @entity99 . The clinical course of @entity99 is more frequently benign but a fulminant severe course is also described. The @entity2131 can be explosive and severe and it is usually fatal if untreated, no correlations have been observed between severity of @entity99 and @entity5066 . In none of the studies a specific virus could be identified and most cases are seronegative for known @entity99 viruses. The clinical characteristics and response to immunotherapy indicate a central role for immune-mediated mechanism in the pathogenesis of @entity2150 . The initial target organ of the immune response is the liver as suggested by the time interval between @entity99 and the onset of @entity2131 . Liver histology is characterized by T cell infiltrating the parenchyma as reported in @entity99 . Recently in @entity2150 it has been demonstrated intrahepatic and blood lymphocytes with T cell repertoire similar to that of confirmed viral @entity99 . The expanded T cell clones return to a normal distribution after response to immunosuppressive treatment, suggesting the antigen or T cell clearance. Therapeutic options are the same as acquired @entity2150 .
